Difference between revisions of "Category:Graft versus host disease medications"

Revision as of 19:02, 2 August 2017

Medications used to treat the symptoms of graft versus host disease (GVHD). Ibrutinib (Imbruvica) is the only currently FDA-approved therapy for the treatment of chronic GVHD.

This category has only the following subcategory.

The following 9 pages are in this category, out of 9 total.

Revision as of 19:02, 2 August 2017 (view source) Jwarner (talk \| contribs) (Created page with "Medications used to treat the symptoms of graft versus host disease (GVHD). Ibrutinib (Imbruvica) is the only currently ''FDA-approved'' therapy for the treatment of c...")		Revision as of 19:02, 2 August 2017 (view source) Jwarner (talk \| contribs) m Newer edit →
Line 1:		Line 1:
	Medications used to treat the symptoms of [[graft versus host disease (GVHD)]]. [[Ibrutinib (Imbruvica)]] is the only currently ''FDA-approved'' therapy for the treatment of chronic GVHD.		Medications used to treat the symptoms of [[graft versus host disease (GVHD)]]. [[Ibrutinib (Imbruvica)]] is the only currently ''FDA-approved'' therapy for the treatment of chronic GVHD.
		+
		+	[[Category:Transplant medications]]